Search results
Results from the WOW.Com Content Network
Later symptoms of ovarian cancer are due to the growing mass causing pain by pressing on other abdominopelvic organs or from metastases. [26] [30] [31] Because of the anatomic location of the ovaries deep in the pelvis, most masses are large and advanced at the time of diagnosis. [14] The growing mass may cause pain if ovarian torsion develops ...
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
An example of a cancer study powered for a combined endpoint is disease-free survival; trial participants experiencing either death or discovery of any recurrence would constitute the endpoint. Overall Treatment Utility is an example of a multidimensional composite endpoint in cancer clinical trials. [8]
Promising results have been reported from a phase II clinical trial for ovarian cancer [5] and endometrial cancer. [6] Phase II trials have also been undertaken for prostate, breast and bladder cancer, although no results for these trials have been reported in peer-reviewed literature. A phase I trial in prostate cancer indicated that nine out ...
According to research, most ovarian cancers start at the epithelial layer which is the lining of the ovary. Within this epithelial group ovarian clear-cell carcinoma makes up 5–10%. It was recognized as a separate category of ovarian cancer by the World Health Organization in 1973. Its incidence rate differs across various ethnic groups.
Roughly 15% of ovarian cancers are detected at the early stage, at which the 5-year survival rate is 92%. [33] A Norwegian meta-analysis of 22 randomized studies involving early-stage ovarian cancer revealed the likelihood that 8 out of 10 women treated with cisplatin after the initial surgery were overtreated. [34]
OGCT is a rare tumour under the scope of ovarian cancer, accounting for less than 5% of all ovarian malignancies. It occurs mostly in 15-19-year-old women and shows 75% incidence rate for women aged <30 years. [31] In 2011, the number of new cases occurred worldwide is 5.3 per million. [32]
Ovarian cancer is a type of cancer which begins in the ovaries. Anyone with ovaries can get it, including women, trans men, non-binary people and intersex people. [2] Although ovarian cancer is much less frequent, it is the deadliest among gynecologic cancers. [3] Early signs of possible breast cancer